CD44 and chronic myelogenous leukemia, BCR-ABL1 positive: According to Moon HJ’s work, nonsteroidal anti-inflammatory drugs (NSAIDs) could reverse the resistance of human chronic myeloid leukemia K562 cells with high CD44 expression to 17-AAG (a Hsp90 inhibitor) and sensitize these cells to 17-AAG, which indicates that NSAIDs in coordination with Hsp90 inhibitor might synergistically potentiate the eradication effects on CSCs with CD44-overexpression [138].